ACUVUE THERAVISION WITH KETOTIFEN Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474746 | JOHNSON JOHNSON VISN | Methods for stabilizing oxidatively unstable compositions |
Mar, 2028
(3 years from now) | |
| US9962376 | JOHNSON JOHNSON VISN | Methods and ophthalmic devices used in the treatment of ocular allergies |
Jun, 2030
(6 years from now) | |
Acuvue Theravision With Ketotifen is owned by Johnson Johnson Visn.
Acuvue Theravision With Ketotifen contains Ketotifen Fumarate.
Acuvue Theravision With Ketotifen has a total of 2 drug patents out of which 0 drug patents have expired.
Acuvue Theravision With Ketotifen was authorised for market use on 25 February, 2022.
Acuvue Theravision With Ketotifen is available in drug-eluting contact lens;ophthalmic dosage forms.
The generics of Acuvue Theravision With Ketotifen are possible to be released after 27 June, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS;OPHTHALMIC
More Information on Dosage
ACUVUE THERAVISION WITH KETOTIFEN family patents
